Inclusion Criteria
	Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment) 
	Serum creatinine =< 1.5 X upper limit of normal (ULN) OR measured or calculated creatinine clearance (glomerular filtration rate [GFR] can also be used in place of creatinine or creatinine clearance [CrCl]) >= 60 mL/min for subject with creatinine levels > 1.5 X institutional ULN
•	Creatinine clearance should be calculated per institutional standard
	Serum total bilirubin =< 1.5 X ULN OR direct bilirubin =< ULN for subjects with total bilirubin levels > 1.5 ULN 
	Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 X ULN OR =< 5 X ULN for subjects with liver metastases

Exclusion Criteria
	Patients with active hemoptysis 
	Any contraindication to MRI (i.e. patients with pacemakers or other metal implanted medical devices); an MRI safety questionnaire is required prior to magnetic resonance (MR) imaging 
	Has a history of (non-infectious) pneumonitis that required steroids or current pneumonitis 
	Has a known human immunodeficiency virus (HIV), hepatitis B (HBV), or hepatitis C (HCV) infection
	Has received a live vaccine within 30 days prior to the first dose of trial treatment
	Inadequately controlled hypertension (defined as systolic blood pressure > 150 mmHg and/or diastolic blood pressure > 100 mmHg); anti-hypertensive therapy to achieve these parameters is allowable
	History of myocardial infarction or unstable angina within 3 months prior to cycle 1, day 1 
	History of stroke or transient ischemic attack within 3 months prior to cycle 1, day 1
